ArticlePsychiatry and clinical neurosciences2026
Immune dysregulation in mania: A proof-of-concept platelet proteomics study.
Article in Psychiatry and clinical neurosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsBipolar disorder (BD) is a major psychiatric condition with a multifaceted and largely unknown pathophysiology. Mania, the defining feature of BD, remains underinvestigated. Proteomics offers a powerful, data-driven, unbiased approach to uncover biological alterations. Blood platelets provide a stable and comprehensive reflection of the body's internal milieu. This proof-of-concept study explores platelet proteomic alterations in mania.
methodsHigh-resolution proteomic profiling was performed on platelet samples from hospitalized patients with severe mania (n = 11) and 1:1 age- and sex-matched healthy controls (n = 11) using liquid chromatography-tandem mass spectrometry. Platelet proteins were quantified, differentially expressed proteins identified, and functional enrichment analyses conducted to characterize associated biological pathways. Key proteomic predictions were validated by enzyme-linked immunosorbent assay (ELISA) in platelet and plasma samples.
resultsProteomic analysis revealed that mania is associated with proteins primarily enriched in immune activation while lacking those enriched in cell homeostasis. Among shared proteins, mania exhibited a prominent cluster of downregulated proteins, primarily converging on immune-related pathways. The most robust alteration involved deficits in MHC Class I-mediated antigen processing. Key immune regulatory hubs - transforming growth factor (TGF)-β and interleukin-4 (IL-4) - were identified, with the association of increased TGF-β levels with mania validated by ELISA.
conclusionsThis study highlights platelet proteomics as a valuable tool for investigating biological alterations in psychiatric disorders. Our findings indicate deficits in MHC Class I-related pathways and immune alterations consistent with chronic low-grade inflammation, suggesting potential roles for latent viral and autoimmune-related mechanisms in BD. These results support and refine the concept of immune dysregulation in mania and BD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.